Construction and identification of eukaryotic plasmid pGC-silencer-U6/Neo/GFP/ABCG2.
- Author:
Yanping YU
1
;
Song ZHANG
;
Weijia KONG
Author Information
1. Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- Publication Type:Journal Article
- MeSH:
ATP Binding Cassette Transporter, Subfamily G, Member 2;
ATP-Binding Cassette Transporters;
genetics;
Cell Line, Tumor;
Gene Expression;
Genetic Vectors;
Humans;
Nasopharyngeal Neoplasms;
genetics;
Neoplasm Proteins;
genetics;
Plasmids;
RNA Interference;
RNA, Messenger;
genetics;
RNA, Small Interfering;
Transfection
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2010;24(17):795-798
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To construct three short hairpin RNA (shRNA) interference expression plasmid vectors of human ABCG2 gene, to assay the expression of ABCG2 in a human nasopharyngeal carcinoma (NPC) cell line, CEN-2 cell line, and to detect the RNAi effect of shRNA.
METHOD:Targeting ABCG2 gene sequence, three plasmid expression vectors coding for shRNA and a control vector containing random DNA fragment were constructed. The recombinant plasmids were amplified in Ecoli. DH5 and then identified by restriction digestion, PCR and sequencing. The recombinant plasmids were transfected into CEN-2 cells. ABCG2 expression was assayed by real-time quantitative PCR and Western blot.
RESULT:The construction of pGC-silencer-U6/Neo/GFP/ABCG2 was succeed. The shRNA plasmids significantly down-regulated the ABCG2 expression in CEN-2 cells, at both mRNA level and protein level. Recombinant plasmid 1 had the strongest effect compared with plasmids 2 and 3 (P < 0.05), with an inhibition ratio of 75% at the mRNA level and 68% at the protein level.
CONCLUSION:pGC-silencer-U6/Neo/GFP/ABCG2 has been successfully constructed and it can down-regulate ABCG2 expression after transfected into CEN-2 cells, which could help further studies of ABCG2 functions CEN-2 cell line and contribute to the NPC gene therapy.
